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Potent immunosuppressive mechanisms within the tumor micro-
environment contribute to the resistance of aggressive human
cancers to immune checkpoint blockade (ICB) therapy. One of the
main mechanisms for myeloid-derived suppressor cells (MDSCs) to
induce T cell tolerance is through secretion of reactive nitrogen
species (RNS), which nitrates tyrosine residues in proteins involved
in T cell function. However, so far very few nitrated proteins have
been identified. Here, using a transgenic mouse model of prostate
cancer and a syngeneic cell line model of lung cancer, we applied a
nitroproteomic approach based on chemical derivation of 3-
nitrotyrosine and identified that lymphocyte-specific protein tyro-
sine kinase (LCK), an initiating tyrosine kinase in the T cell receptor
signaling cascade, is nitrated at Tyr394 by MDSCs. LCK nitration
inhibits T cell activation, leading to reduced interleukin 2 (IL2) pro-
duction and proliferation. In human T cells with defective endog-
enous LCK, wild type, but not nitrated LCK, rescues IL2 production.
In the mouse model of castration-resistant prostate cancer (CRPC)
by prostate-specific deletion of Pten, p53, and Smad4, CRPC is re-
sistant to an ICB therapy composed of antiprogrammed cell death
1 (PD1) and anticytotoxic–T lymphocyte-associated protein 4
(CTLA4) antibodies. However, we showed that ICB elicits strong
anti-CRPC efficacy when combined with an RNS neutralizing
agent. Together, these data identify a previously unknown mech-
anism of T cell inactivation by MDSC-induced protein nitration and
illuminate a clinical path hypothesis for combining ICB with RNS-
reducing agents in the treatment of CRPC.
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Inhibition of cytotoxic T lymphocytes by immunosuppressivecells represents a significant contributing mechanism to im-
munotherapy resistance (1). Among the immunosuppressive cells,
myeloid-derived suppressor cells (MDSCs) are immature myeloid
cells that maintain T cell tolerance (2, 3). Activation of MDSCs is
usually manifested by up-regulation of arginase 1 (ARG1) and
inducible nitric oxide synthase (iNOS), as well as increased pro-
duction of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) such as peroxynitrite (2). MDSCs are phenotypi-
cally divided into granulocytic (Gr-MDSCs) and monocytic (Mo-
MDSCs) subpopulations (2). Both MDSC subgroups inhibit
T cells through NO-related pathways, and the primary mechanism
by Gr-MDSCs is through production of ROS and RNS (4). RNS
has emerged as a potent chemical modifier to induce nitration of
chemokines and receptors on T cells, creating a “chemical barrier”
to restrict T cell infiltration and impair T cell functions (5).
Protein nitration, a form of posttranslational modification,
usually occurs at the 3′-position of the phenolic ring of tyrosine
(Tyr) to form 3-nitrotyrosine (3-NT). Up-regulation of 3-NT is
documented in various human cancers, including prostate cancer
(6–9). In MDSCs, both endothelial NO synthase (eNOS) and
iNOS contribute to the production of NO. NO reacts with su-
peroxide O2
•− rapidly and forms RNS such as peroxynitrite
(ONOO−) and the free radical nitrogen dioxide (•NO2), which
lead to Tyr nitration (5, 10, 11). Due to the different chemical
properties between Tyr and 3-NT, a nitrated protein may have
perturbed signaling activity (10, 11). Tyr nitration has been
documented to either positively or negatively regulate Tyr phos-
phorylation (12, 13). Protein nitration as a type of oxidative
damage is highly relevant to aging and diseases including cancer
(10, 11). MDSC-derived peroxynitrite could cause nitration of the
T cell receptor (TCR)–CD8 complex and reduce its binding to
peptide–major histocompatibility complex (14). Nitration of CCL2
by MDSC-derived peroxynitrite impairs the infiltration of effector
CD8+ T cells (7). Previous studies also showed that peroxynitrite
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perturbed Tyr phosphorylation and inhibited T cell activation (6,
15). However, these studies did not identify specific nitrated Tyr
sites on proteins involved in T cell function. To identify the precise
3-NT sites, a global mass spectrometry (MS)-based profiling ap-
proach is needed. However, mapping nitration sites is challenging,
due to low abundance of this modification in biological samples
(16). Currently, an enrichment technique followed by MS is the
most powerful approach for detecting nitropeptides. Enrichment
procedures include use of either 3-NT specific antibodies or
chemical derivation that reduces a nitro group to an amine group
(17–19). Most previous studies aimed at methodology develop-
ment and used in vitro overnitrated samples to profile artificially
nitrated instead of endogenously nitrated proteins.
In this study, we developed a chemical derivation method
to profile endogenous nitropeptides from tumor-infiltrating
T cells of two cancer models and identified a shared nitration
site at lymphocyte-specific protein tyrosine kinase (LCK)
(Tyr394) with functional impact. We showed the accumulation
of 3-NT in clinical samples of castration-resistant prostate cancer
(CRPC), a lethal disease overwhelmingly resistant to immune
checkpoint blockade (ICB) (20). Importantly, in a CRPC mouse
model we recently developed (21), CRPC can be sensitized to
ICB treatment when RNS is neutralized in a combination
therapy setting.
Results
Induction of Protein Nitration by Intratumoral MDSCs. We first
compared the concentration of nitrite between spontaneous prostate
tumors from the Pten/p53/Smad4 model (21, 22) and normal
prostate from age-matched wild-type C57BL/6 mice, as well as be-
tween Lewis lung carcinoma (LLC) s.c. tumors and normal lung
from age-matched C57BL/6 mice. In both cases, the tumor lysates
contained four- to sixfold higher nitrite level compared with normal
tissues (Fig. 1A). In accordance with increased nitrite level, Pten/
p53/Smad4 and LLC tumors exhibited significantly augmented 3-NT
level detected by immunoblot (Fig. 1 B and C) and immunohisto-
chemistry (SI Appendix, Fig. S1A). The 3-NT signals were attenu-
ated by Na2S2O4 treatment, which reduces 3-NT to 3-aminotyrosine.
To examine the relative contribution of tumor and stromal com-
partments to the 3-NT signals, we utilized the Pten/p53/Smad4/
mTmG model (21), which allowed separation of GFP+ tumor cells
and tdTomato+ stromal cells. The result showed that both com-
partments contained significant level of 3-NT (SI Appendix, Fig.
S1B). MDSC infiltration was reported in both Pten/p53/Smad4
model and LLC model: in the case of Pten/p53/Smad4 prostate
tumors, we recently identified Gr-MDSCs as the dominant intra-
tumoral MDSC population (21); in the case of LLC tumors, com-
parable frequency of Gr-MDSCs and Mo-MDSC were detected (SI
Appendix, Fig. S1C), consistent with previous report (23). Compared
with circulating neutrophils from tumor-free mice, both Gr-MDSCs
and Mo-MDSCs from the LLC model generated dramatically in-
creased amount of nitrite, with Mo-MDSCs producing moderately
higher (SI Appendix, Fig. S1D), a result consistent with previous
report (4). We also isolated intratumoral MDSCs and tumor-
associated macrophages (TAMs) from CD11b+ cell populations in
both models and found that MDSCs produced a higher level of
nitrite compared with TAMs (SI Appendix, Fig. S1 E and F).
To show whether MDSCs induce protein nitration in T cells, we
isolated total T cells from spleen of wild-type mice, activated with
anti-CD3/anti-CD28 antibodies in the presence or absence of
coculture with MDSCs isolated from the spleen or primary
prostate tumors of the Pten/p53/Smad4 model. The T cells were
subsequently isolated from the coculture for Western blot of 3-
NT. Peroxynitrite treatment in the process of T cell activation was
used as a positive control. The 3-NT bands were detected by both
splenic and intratumoral MDSC coculture, although intratumoral
MDSCs induced stronger 3-NT signals (Fig. 1D). The protein
nitration returned to basal level when uric acid (UA), a potent
peroxynitrite neutralizer (14), was added to the coculture of
T cells with intratumoral MDSCs. Induced T cell activation turned
on production of IL2, which was largely abrogated by intratumoral
MDSC coculture or peroxynitrite treatment (Fig. 1E). Activation
markers for cytotoxic T cells, including INF-γ, perforin, and
granzyme B, were also down-regulated by MDSC coculture or
peroxynitrite treatment (SI Appendix, Fig. S1G). Intratumoral
MDSCs isolated from LLC tumors also induced 3-NT signals and
reduced IL2 production in T cells (SI Appendix, Fig. S1 H and I).
Together, these data showed induction of protein nitration and
correspondingly reduced IL2 secretion in T cells by intratumoral
MDSCs in two independent mouse models.
Development of a Method for Nitropeptide Profiling. To identify
specific nitration sites, we developed a method of nitropeptide
enrichment and profiling. We used Angiotensin II (Ang II) as
the model peptide for the methodology development (Fig. 2A).
Ang II was nitrated by peroxynitrite, followed by alkylation using
formaldehyde to block the primary amine. Next, 3-NT was re-
duced by Na2S2O4 to generate 3-aminotyrosine, which was fur-
ther labeled with NHS-S-S-biotin and enriched by streptavidin
beads. For the detection, the enriched peptides were eluted by
dithiothreitol (DTT) and modified by iodoacetamide (IAA). The
final product was analyzed by liquid chromatography–tandem
mass spectrometry (LC-MS/MS). The monoisotope peak of Ang
II was at 523.78m/z with duple charge (SI Appendix, Fig. S2 A, i),
and the fragmentation pattern of this peptide was featured by the
two highest peaks in the low m/z range: y2 ion at 263.14 and
immonium ion of His at 110.07 (SI Appendix, Fig. S2B). After
nitration by peroxynitrite, the monoisotope peak with the duple
charge shifted to 546.28 m/z, indicating 45 Da larger than the
original Ang II (SI Appendix, Fig. S2 A, ii). Dimethyl labeling and
reduction of the nitro group increased the molecule weight by 28
Da (560.29 m/z) and reduced it by 30 Da (545.31 m/z), re-
spectively (SI Appendix, Fig. S2 A, iii and iv). All of the MS/MS of
these intermediate products were shown in SI Appendix, Fig. S2
C–E. After the peptide enrichment, reduction, and alkylation,
the monoisotope peak of the final product was detected at
617.82 m/z with duple charge, which corresponded to a +160 Da
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Fig. 1. Intratumoral MDSCs induce protein nitration. (A) Comparison of
relative nitrite concentration in Pten/p53/Smad4 spontaneous tumor with
wild-type (WT) prostate (Left) and LLC s.c. tumor with WT lung (Right) (n =
3). (B) Western blot of 3-NT of WT prostate and Pten/p53/Smad4 sponta-
neous tumor. (C) Western blot of 3-NT of WT lung and LLC s.c. tumor.
Na2S2O4 treatment of the blot membrane converted 3-NT to 3-aminotyrosine
and eliminated signals. (D) Primary T cells isolated fromWTmouse spleen were
stimulated by anti-CD3/CD28 condition for 48 h in the absence or presence of
MDSCs isolated from Pten/p53/Smad4 tumor or spleen. Peroxynitrite at 50 μM
or uric acid at 50 μM were added as indicated. Whole cell lysates of isolated
T cells were immunoblotted for 3-NT. (E) Primary T cells were treated as in D,
and the IL2 concentration of each sample was measured in the medium using
ELISA (n = 2). In A and E, data represent mean ± SD. *P < 0.05, ***P < 0.001,
Student’s t test.
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modification on Tyr residue (SI Appendix, Fig. S2 A, v). The
fragmentation spectrum of the final product also confirmatively
showed the characteristic peaks of Ang II (y2 ion, immonium ion
of His) and was composed of the mixed pattern of a, b series ions
and c0, α cleavage at the N terminus of the peptide (SI Appendix,
Fig. S2F). Together, this chemical modification method allowed
us to enrich nitropeptides for the unbiased profiling purpose.
Identification of Protein Nitration at LCK (Tyr394). We applied the
aforementioned methodology and focused on profiling nitro-
peptides of tumor-infiltrating T lymphocytes isolated from both
Pten/p53/Smad4 and LLC models, with total resting splenic T cells
from tumor-free C57BL/6 mice as control. For the Pten/p53/
Smad4 model, intratumoral T cell lysate and normal T cell lysate
were labeled with light and heavy formaldehyde, respectively.
Conversely, for the LLC model, intratumoral T cell lysate and
normal T cell lysate were labeled with heavy and light formalde-
hyde, respectively. The enriched peptides were injected into Q
Exactive MS instrument, and pFind Studio software was used for
the proteomic data search by adding +160 Da modification on Tyr
residues. We identified 14 nitropeptides from the Pten/p53/Smad4
model and 12 nitropeptides from the LLC model (SI Appendix,
Fig. S3). The proteins containing the nitropeptides are involved in
cellular mechanisms such as metabolism, signal transduction, cy-
toskeletal motility, and protein degradation. Surprisingly, we
identified a unique overlap of these two lists, LIEDNEY*TAR, of
which the Tyr residue is the 394th residue of lymphocyte-specific
protein tyrosine kinase (LCK). Specifically, the monoisotope
peaks at 706.33 and 708.35 m/z with duple charge indicated the
light and heavy formaldehyde-labeled peptides in Pten/p53/Smad4
and LLC tumor samples, respectively (Fig. 2 B and C). Both MS/MS
showed the fragmentation pattern that matched the y series of
ions, which further validated Tyr394 of LCK as a commonly
nitrated protein in T cells from both tumor models (Fig. 2 D and E).
To directly test whether MDSCs induce Tyr394 nitration on LCK in
T cells, we used multiple reaction monitoring (MRM)-MS and
quantified the relative amount of the LCK peptide, LIEDNEY(nitro)
TAR, from anti-CD3/CD28–stimulated splenic T cells under condi-
tions of no treatment, MDSC coculture, and peroxynitrite treatment.
For each of the y6, y7, and y8 ions, almost no peaks were detected in
untreated condition, whereas MDSC coculture or peroxynitrite
treatment induced dramatic increase of the specific nitropeptide (Fig.
2 F and G). Our results indicate that RNS produced by MDSCs can
induce LCK Tyr394 nitration on mouse primary T cells.
LCK Nitration Suppresses T Cell Activation. LCK is an Src-family
protein kinase and serves as the initiating tyrosine kinase in the
TCR activation pathway (Fig. 3A). Similarly to Src, LCK activity is
regulated by tyrosine phosphorylation at two sites, but with opposing
effects: autophosphorylation on Tyr394 up-regulates the catalytic
activity, while phosphorylation on Tyr505 down-regulates the activity
(24). We hypothesized that Tyr394 nitration might lead to attenu-
ated LCK activity and dampened TCR signaling. We used the im-
mortalized human T cell line Jurkat to study how peroxynitrite and
LCK nitration affect T cell function. While moderate concentrations
of peroxynitrite (5 μM, 10 μM) did not affect Jurkat cell pro-
liferation, high peroxynitrite (≥25 μM) showed dose-dependent in-
hibitory effect on Jurkat cell proliferation (SI Appendix, Fig. S4A).
Fig. 2. Methods for nitropeptide enrichment and identification of nitro-Tyr394 peptide LIEDNEYTAR in LCK from both mouse models. (A) The workflow of
the chemical derivation method for detecting nitrated Ang II. (B) The MS of the modified LCK peptide from T cells of the Pten/p53/Smad4 tumors. The mon-
oisotope peak at m/z 706.33 matched the duple-charged, CH2O-labeled peptide. (C) The MS of the modified LCK peptide from T cells of the LLC tumors. The
monoisotope peak atm/z 708.35 matched to the duple-charged, CD2O-labeled peptide. (D and E) The MS/MS of B and C, respectively. (F) The intensities of y6, y7,
and y8 ions of LIEDNEY(nitro)TAR in stimulated T cells (black), stimulated T cells cocultured with MDSCs (red) and stimulated T cells treated with peroxynitrite
(blue) (n = 3). The data were acquired by MRM-MS, and each sample was performed by two technical replicates. (G) Normalized abundance of LIEDNEY(nitro)
TAR in three cell conditions as in F by using two reference peptides from actin (see Methods). Data represent mean ± SD. **P < 0.01, Student’s t test.
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Jurkat cells can be stimulated to produce IL2 by either anti-
CD3/CD28 antibodies or phorbol 12-myristate 13-acetate
(PMA)/ionomycin. We found that peroxynitrite modulated the
IL2 production by Jurkat cells in a stimulation-specific manner:
inhibition of T cell activation (indicated by lowered IL2 production)
was more sensitive to peroxynitrite when Jurkat were stimulated by
anti-CD3/CD28 compared with stimulation by PMA/ionomycin
(Fig. 3B). Because anti-CD3/CD28 stimulation occurs at the most
upstream of the TCR signaling pathway, whereas PMA/ionomycin
bypasses the early steps and directly triggers PKC activation and
Ca2+ release, we argue that the primary effect of peroxynitrite was
due to inactivation of the upstream signaling mediators, including
LCK. To test this hypothesis, we surveyed the status of a number
of upstream components of the TCR signaling pathway and
detected consistent down-regulation of phospho-LCK (Tyr394,
Tyr505), phospho-Zap70 (Tyr319), phospho-LAT (Tyr191), and
phospho-PLCγ1 (Tyr783) as a response to peroxynitrite treatment
in anti-CD3/CD28–stimulated Jurkat cells (Fig. 3C). Concomi-
tantly, peroxynitrite induced the formation of nitrated LCK,
indirectly detected by immunoprecipitation of LCK and im-
munoblot of 3-NT (SI Appendix, Fig. S4B). Because there are
differences in the phosphorylation cascade of the T cell activa-
tion pathway between the Jurkat cell line and primary T cells
(25), human primary T cells were purified from peripheral blood
mononuclear cells (PBMCs), activated with anti-CD3/CD28
antibodies, and treated by peroxynitrite. Similar to Jurkat cells,
phosphorylation of LCK, Zap70, LAT, and PLCγ1 was attenuated
by peroxynitrite (SI Appendix, Fig. S4C). By coculturing human
primary T cells with intratumoral MDSCs from the Pten/p53/Smad4
model, we detected more than 10-fold increase of nitro-Tyr394
LCK peptide LIEDNEY(nitro)TAR using MRM (Fig. 3 D and E).
Fig. 3. Effects of nitration on LCK and T cell activation. (A)
Brief scheme of T cell activation pathway. (B) Relative IL2
concentration in medium of Jurkat cells stimulated with PMA/
ionomycin (blue) or anti-CD3/CD28 antibodies (red) in the
presence of different concentrations of peroxynitrite, mea-
sured by ELISA (n = 2). (C) Immunoblot analysis of phospho-
tyrosine levels of a number of signaling proteins in the T cell
activation pathway, with lysates purified from Jurkat cells
stimulated with anti-CD3/CD28 antibodies in the presence
of peroxynitrite. (D) The intensities of y6, y7, and y8 ions of LIED-
NEY(nitro)TAR in stimulated primary human T cells (black),
stimulated T cells cocultured with MDSCs from Pten/p53/Smad4
tumors (red), and stimulated T cells treated with peroxynitrite
(blue) (n = 3). The data were acquired by MRM-MS, and each
sample had two technical replicates. (E) Normalized abundance
of LIEDNEY(nitro)TAR in three cell conditions as in D by using
two reference peptides from actin. (F) The MS/MS of tryptic
nitro–Tyr394-containing peptide in recombinant LCK. The par-
ent ion is at 634.79 m/z in duple charge. (G) Relative in intro
enzymatic activity of recombinant human LCK inducted with
different concentrations of peroxynitrite. Under each concentra-
tion of peroxynitrite treatment, the enzyme activity was mea-
sured twice. (H) Effect on IL2 production by J.CaM1.6 cells, which
were stimulated with anti-CD3/CD28 antibodies and transfected
with unmodified or nitrated LCK. Data were normalized to PMA/
inomycin stimulation (n = 3). In B, E, G, and H, data represent
mean ± SD. **P < 0.01, ***P < 0.001, Student’s t test.
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To study LCK nitration in a cell-free system, we treated
recombinant human LCK protein with 50 μM peroxynitrite, and
the Tyr394 nitration site was readily detected by MS (Fig. 3F), in
addition to two other previously uncharacterized nitration sites
Tyr192 and Tyr414 (SI Appendix, Fig. S4 D and E). To demon-
strate that nitration causes “loss of function” of LCK, we gen-
erated in vitro nitrated LCK with different concentrations of
peroxynitrite and measured its catalytic activity in comparison
with untreated LCK protein. When peroxynitrite concentration
was below 50 μM, nitration caused a dose-dependent reduction
of LCK activity (Fig. 3G). Surprisingly, when peroxynitrite con-
centration was above 100 μM (i.e., at the level with significant
cytotoxicity to T cells), LCK activity recovered and gradually
reached an even higher level than no treatment control (SI Ap-
pendix, Fig. S4F; see Discussion). The inhibitory effect of nitra-
tion on LCK was further assessed in a functional rescue
experiment using the J.CaM1.6 cell line. J.CaM1.6 is a derivative
mutant of Jurkat with a defective LCK and inability to produce
IL2 upon anti-CD3/CD28 stimulation (26). Transfection of
J.CaM1.6 with untreated recombinant LCK rescued the IL2
production by anti-CD3/CD28 stimulation to the level compa-
rable with PMA/ionomycin stimulation (Fig. 3H). However, LCK
pretreated with 10 or 25 μM peroxynitrite partially lost the ability
to rescue IL2 production (Fig. 3H and SI Appendix, Fig. S4G).
To investigate whether phosphorylation on Tyr394 is adversely
affected by peroxynitrite treatment, the autophosphorylation
reaction of LCK was performed, and the amount of phosphor-
ylated LIEDNEYTAR was monitored by MRM. About 60% of
Tyr394 autophosphorylation was reduced by pretreatment of
LCK with 25 μM peroxynitrite (SI Appendix, Fig. S4 H and I).
Taken together, the results nominate LCK as a key target for
RNS-induced protein nitration as part of the integrated process
of T cell suppression by MDSCs.
RNS Neutralization Sensitizes CRPC to Immunotherapy. There is
significant up-regulation of 3-NT in human prostate cancer (6–
9), consistent with the abundant tumor-infiltrating MDSCs in
clinical prostate cancer (21). To assess 3-NT in CRPC, we per-
formed immunohistochemistry (IHC) of 3-NT for a small set of
human primary CRPC samples (n = 15) and observed that while
adjacent normal-like prostate stained negatively, 40% (6/15) of
CPRC cases stained positively (Fig. 4A). We determined that both
cancer cells (pan-cytokeratin+) and T cells (CD3+) were stained
positive for 3-NT using IHC costaining (Fig. 4A). Consistent with
the human sample results, we also detected that both cancer cells
(pan-cytokeratin+, strong in Pten/p53/Smad4 tumors, weak in
LLC tumors) and T cells (CD3+) were stained positive for 3-NT
using IHC costaining for the two mouse models (SI Appendix, Fig.
S5A). We recently showed that the Pten/p53/Smad4 prostate tu-
mors developed into CRPC after surgical castration and enzalu-
tamide treatment, which was refractory to an ICB treatment
composed of anti-CTLA4 and anti-PD1 antibodies (21). To de-
termine whether blocking RNS activity using UA would sensitize
CRPC to ICB, we enrolled Pten/p53/Smad4 mice into a preclinical
trial in a similar fashion as our previous report (21) and treated
the randomized cohorts of CRPC-bearing mice with vehicle + isotype
IgG (control), anti-CTLA4 and anti-PD1 antibodies (ICB), UA, or
ICB + UA for 1 mo. At the endpoint, we observed significant syn-
ergistic efficacy by the ICB + UA treatment while ICB or UA alone
produced marginal effect (Fig. 4 B and C). The tumors treated with
UA were verified to show significantly reduced 3-NT signals (Fig.
4D), and the tumor-infiltrating T cells from UA-treated mice had
moderately increased transcriptional level of IL-2, INF-γ, perforin,
and granzyme B (SI Appendix, Fig. S5B). Significant reduction of 3-
NT signals in the Pten/p53/Smad4 tumors was also verified when
MDSCs were depleted using anti-Gr-1 antibody (SI Appendix, Fig.
S5C), for which the depletion experiment was performed in our re-
cent study (21). This result reinforces the conclusion that MDSCs can
account for a large fraction of RNS-induced protein nitration.
We evaluated the effect of ICB, UA, and ICB + UA on the
number of infiltrating CD8+ T cells and Foxp3+ Tregs in the
treated tumors (SI Appendix, Fig. S5D) and found that ICB
moderately increased CD8+ T cells (Fig. 4E) and reduced
Foxp3+ Tregs (Fig. 4F). Importantly, while UA alone caused no
change of infiltration of CD8+ T cells or Tregs, UA elicited
strong synergistic effect with ICB to boost the number of infiltrating
CD8+ T cells (Fig. 4E). As a result, ICB+UA resulted in over sixfold
increase of CD8+ T/Treg ratio compared with control, which was
threefold increase compared with ICB alone (Fig. 4G). UA single
treatment did not change the infiltration of myeloid cells or B cells, as
shown by IHC of CD11b, Ly6G, F4/80, CD11c, and B220 (SI Ap-
pendix, Fig. S5E). Furthermore, the synergistic antitumor effect by
ICB+UA treatment was also observed for the LLCmodel (Fig. 4H).
In short, RNS neutralization using UA synergizes with ICB to induce
strong antitumor effect in both CRPC and lung cancer models.
Discussion
Here, by applying a nitroproteomic approach to two mouse tu-
mor models, we identified specific nitration of LCK(Tyr394) by
intratumoral MDSCs as a mechanism of immunosuppression.
Neutralizing RNS was shown as an effective strategy to combine
with ICB to elicit strong tumor inhibitory effect in the models, a
result with clinical implications in combating emerging resistance
to cancer immunotherapy.
The composition of Gr-MDSCs and Mo-MDSCs in the two
models differs: while Gr-MDSCs account for over 90% of total
MDSCs in the Pten/p53/Smad4 tumors (21), Gr-MDSCs and
Mo-MDSCs are comparable in the LLC tumors (SI Appendix,
Fig. S1C). While Mo-MDSCs secreted a higher level of nitrite
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Fig. 4. Combinational therapy of the mouse CRPC and LLC model. (A) Repre-
sentative 3-NT IHC images of adjacent normal or CPRC samples (n = 15) and the
costaining pattern of 3-NT with pan-cytokeratin (pan-CK) or CD3. (Scale bar,
100 μm.) DAB and VIP refer to 3, 3-diaminobenzidine and violet peroxidase sub-
strate, respectively. The black open circle in top right image was an accidentally
trapped air bubble. (B) Preclinical trial result of prostate tumor mass of the Pten/
p53/Smad4 CRPC model (n = 6, 5, 6, 5, respectively). (C) Representative prostate
images of the preclinical trial in B. (Scale bar, 3 mm.) (D) Immunoblot analysis of 3-
NT levels in whole prostate lysates from the preclinical trial in B. (E) Quantification
of infiltrating CD8+ T cells based on CD8 IHC of CRPC samples from the preclinical
trial in B. (F) Quantification of infiltrating Treg cells based on Foxp3 IHC of CRPC
samples from the preclinical trial in B. (G) Ratios of CD8+ T cell numbers over Treg
cell numbers for each treatment condition in the preclinical trial in B. (H) Preclinical
trial result of the LLC s.c. tumormodel (n= 8–10 for each group). In B, ***P< 0.001,
Mann–Whitney U test. In E, F, and H, ***P < 0.001, #P > 0.05, Student’s t test.
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(SI Appendix, Fig. S1D), studies have shown that RNS is essential
for Gr-MDSCs to inhibit T cells (4), and the basal NOS activity
(primarily by eNOS) is sufficient for Gr-MDSCs to produce RNS
(14). Therefore, despite variation of MDSC composition, both
models showed strong RNS activity and induced LCK nitration in
infiltrating T cells.
Our nitroproteomic method improves on two aspects: first,
dimethyl labeling is used for primary amine blocking; second,
after reduction, the newly generated amine group on the phenolic
ring is conjugated with NHS-S-S-biotin reagent and further la-
beled with IAA, which can enhance the ionization efficiency of the
final product. We used Ang II as a model peptide to study
nitration modification. The two characteristic peaks (y2 ion,
immonium ion of His) facilitated identification of intermediate
products during the chemical reaction steps, due to their existence
independent of Tyr residue changes and N terminus blocking.
After dimethyl labeling, the fragmentation pattern became com-
plicated due to c0 and α cleavage at the N terminus of the peptides
(SI Appendix, Fig. S2 D–F), which was deduced to represent six
series of ions (a, b, a-c0, b-c0, a-c0-α, and b-c0-α) on MS/MS.
Similar to other nitroproteomic approaches, our method is limited
by its suboptimal sensitivity. Future improvement is needed to
allow detection of hundreds of endogenously nitrated proteins.
For LCK, phosphorylation on Tyr394 and Tyr505 plays op-
posite roles in regulating the kinase activity (24). Our result showed
that RNS down-regulates phosphorylation at both sites in T cells,
which should predict loss of overall LCK activity. This prediction
was verified with the observation of reduced LCK enzymatic activity
and autophosphorylation at Tyr394 (Fig. 3G and SI Appendix, Fig.
S4 H and I). The precise mechanism for nitration-induced impair-
ment of LCK phosphorylation awaits further investigation because
it is possible that nitration interferes with phosphorylation through
either directly lowering pKa of the hydroxyl group or indirect
conformational change of the protein. An interesting observation
of the nitration-activity relationship of LCK was the activity rise at
higher peroxynitrite concentration (100–1000 μM), which is likely
due to S-nitrosylation of cysteine residues based on studies of an-
other Src family member, HCK (27). At high concentrations
(>100 μM), peroxynitrite induces apoptosis in various cell types
(11). Therefore, the net effect of peroxynitrite on T cells is inhibition.
Because LCK(Tyr394) is a site for both nitration and phosphoryla-
tion, it is technically challenging to show that abolishing nitro-Tyr394,
but not phospho-Tyr394, impairs T cell activation in vivo.
Given that MDSC targeting is most likely applied in a com-
binatorial therapeutic setting, we reason that drugs that block
MDSC function and display favorable safety profiles would
bring the most benefits. Our data indicate that peroxynitrite
scavenger is a promising agent to combine with ICB. A previous
study also demonstrated that UA enhanced a cancer vaccine
therapy in the murine MC38 model (14). These data should
prompt clinical studies exploring the benefit of combining
RNS-reducing agents with immunotherapy. Last, although
MDSCs appear to be a stronger producer of RNS than TAMs
in the two models (SI Appendix, Fig. S1 E and F), we do not rule
out the possibility that the combination therapy efficacy may be a
collective effect of targeting immunosuppressive mechanisms
from multiple immune populations including MDSCs as well as
M2-polarized TAMs.
Materials and Methods
Animal study was approved and overseen by University of Notre Dame In-
stitutional Animal Care and Use Committee. The PB-Cre+ PtenL/L p53L/L
Smad4L/L model (Pten/p53/Smad4) with and without themTmG reporter was
developed previously (21, 22). Mouse cell line Lewis Lung Carcinoma (LLC)
and human cell lines Jurkat and J.CaM1.6 were purchased from American
Type Culture Collection (ATCC) and maintained in Dulbecco’s Modified Eagle
Medium (DMEM) and Roswell Park Memorial Institute (RPMI) 1640 with 10%
fetal bovine serum, respectively. Other detailed methods, including chemical
reactions of Ang II; LC-MS/MS analysis; MRM assay; clinical samples; isolation of
MDSC, macrophages, and T cells; measurements of nitrite concentration, LCK
kinase activity, and IL2 production; combination therapy in mice; and statistics
are available in SI Appendix, Supplementary Materials and Methods.
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